The short answer
Promising, not yet available, and not a miracle. Clascoterone is a topical drug that blocks DHT directly at the hair follicle instead of lowering DHT throughout your whole body — the mechanism finasteride and dutasteride use, and the one usually blamed for their sexual side effects. In two Phase 3 trials (SCALP 1 and SCALP 2, 1,465 men total), it beat placebo by 539% and 168% respectively on hair count, with side effects reported at about the same rate as placebo. It is not FDA-approved, isn't for sale anywhere legitimately yet, and realistic timelines point to a 2027 launch at the earliest, likely priced around $90–150 a month with no insurance coverage. If anyone is trying to sell you "clascoterone for hair loss" today, that is not the real, trial-tested product.
- Status
- Phase 3 complete, not yet approved
- Mechanism
- Topical androgen receptor blocker
- Trials
- SCALP 1 & SCALP 2 (1,465 men)
- Expected availability
- ~2027, earliest
- Estimated cost
- $90–150/month, uninsured
Why so many men never treat their hair loss at all
Before getting into the drug itself, it's worth naming the actual problem it's trying to solve, because it's rarely about the hair loss itself. A huge number of men who'd genuinely benefit from treatment simply never start — not because nothing works, but because the two most effective options, finasteride and dutasteride, come with a well-founded fear of sexual side effects that's loud enough online to talk people out of trying anything at all.
That fear isn't irrational. A systematic review and meta-analysis of 15 randomized controlled trials covering 4,495 men found a 57% higher relative risk of sexual dysfunction with 5-alpha-reductase inhibitors as a class, and about a 66% higher relative risk specifically for finasteride, compared with placebo. Those are real numbers from real trials, not internet folklore.
But relative risk isn't the same as your risk. The absolute rate in most trials sits in the low single digits — most men on finasteride never experience it, and for those who do, it typically resolves after stopping. The problem is that a small, real risk of something permanent and deeply personal is exactly the kind of risk the human brain is worst at sizing up rationally — it looms much larger than the odds actually justify, and for a lot of men that's enough to avoid treatment entirely and just watch it happen instead. That gap — between "effective" and "something I'm actually willing to put in my body" — is precisely the gap clascoterone is designed to close.
What clascoterone actually is, in plain terms
Male pattern baldness is driven by DHT (dihydrotestosterone), a hormone your body already makes, binding to receptors in genetically susceptible hair follicles and gradually shrinking them. Finasteride and dutasteride attack this by blocking the enzyme (5-alpha-reductase) that converts testosterone into DHT — everywhere in your body, not just your scalp. Less DHT overall means less DHT reaching the follicle, but it also means less DHT everywhere else DHT normally does its job, which is where the systemic side effects come from.
Clascoterone takes a different approach entirely. Think of DHT as a key and the receptor on the follicle as a lock. Finasteride tries to make fewer keys everywhere in the building. Clascoterone doesn't touch key production at all — it just changes the lock on one specific door, the scalp, so DHT can't get in there anymore, while DHT levels everywhere else in the body stay exactly as they were.
This isn't a completely unproven idea. The same molecule has been FDA-approved since 2020 as Winlevi, a 1% cream for acne (acne is also partly androgen-driven), giving it real human safety data in a different application before the hair-loss-specific 5% formulation ever reached Phase 3. That's a meaningfully different starting point than a molecule with zero prior human exposure.
The trial data: SCALP 1 and SCALP 2
Cosmo Pharmaceuticals ran two identically designed Phase 3 trials — SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805) — multicenter, randomized, double-blind, vehicle-controlled, enrolling 1,465 men across the United States and Europe. The primary endpoint in both was change in Target-Area Hair Count (TAHC) compared with the inactive vehicle.
SCALP 1 showed a 539% relative improvement over vehicle. SCALP 2 showed a 168% relative improvement. Both hit statistical significance (p<0.05), and the pooled analysis across both trials showed more than 252% relative improvement, also statistically significant.
Worth being honest about: that's a big gap between two trials that were supposedly designed identically. Relative-improvement percentages measured against a small vehicle response can swing a lot between sites and patient populations even when the underlying drug effect is consistent — a modest difference in how much the placebo arm grew hair can swing the "percent better than placebo" number dramatically without the drug's actual effect changing much at all. Cosmo has not yet published the absolute hair-count-per-square-centimeter numbers publicly (unlike some competing trials, which do report those directly), so right now the honest takeaway is "statistically significant improvement in both trials, real magnitude unclear until fuller data or peer-reviewed publication," not "539% better hair growth," which is the headline most coverage has run with.
How it compares to what's already available
A side-by-side of the main options, based on published trial and post-marketing data:
| Aspect | Minoxidil | Finasteride | Dutasteride | Clascoterone |
|---|---|---|---|---|
| Mechanism | Vasodilator; exact hair-growth mechanism still not fully understood | Blocks the enzyme that converts testosterone into DHT, body-wide | Blocks both forms of that enzyme, body-wide (more complete than finasteride) | Blocks DHT from binding its receptor, locally at the scalp |
| Where it acts | Scalp only (topical) | Whole body (oral) | Whole body (oral) | Scalp only (topical); minimal systemic absorption reported so far |
| Sexual side-effect signal | No meaningful signal in the research literature | ≈66% relative increase in sexual dysfunction risk vs. placebo (meta-analysis) | Similar or slightly higher relative risk than finasteride in cohort data | No signal above vehicle/placebo reported in Phase 3 so far |
| Regulatory status (hair loss) | FDA-approved since 1988 | FDA-approved since 1997 (Propecia, 1mg) | Not FDA-approved for hair loss; prescribed off-label | Investigational — Phase 3 complete, not yet submitted for approval |
What's not yet known
A few honest gaps worth knowing before getting too excited:
- No long-term real-world data yet. Everything so far comes from controlled trials lasting up to 12 months. Real-world safety data, the kind that eventually exists for finasteride and minoxidil after decades of use, simply doesn't exist yet for clascoterone at the hair-loss dose.
- A related safety signal exists, even if not seen here yet. The lower-dose acne cream (Winlevi 1%) showed reversible HPA-axis (adrenal) suppression in about 5% of adults in a pharmacokinetic sub-study at day 14, resolving within 4 weeks of stopping. The hair-loss formulation is a stronger 5% concentration applied to a different body area, and while Phase 3 hair trials haven't reported this as an issue so far, it's a legitimate class effect worth watching for in the fuller safety dataset due in spring 2026.
- The absolute effect size isn't public yet. As above — relative-to-vehicle percentages, not hair-count numbers, are what's been released so far.
- It isn't available, at any price, from anyone legitimate. Realistic timelines point to 2027 at the earliest for a U.S. launch, likely around $90–150 a month, uninsured.
Timeline: what happens between now and when you can actually get it
The same molecule, clascoterone, is already FDA-approved as Winlevi, a 1% cream for acne — the first topical androgen-receptor blocker ever approved for skin. This is a repurposed, higher-strength (5%) version of a drug with real human safety data behind it, not a brand-new, never-tested molecule.
Cosmo Pharmaceuticals announces topline Phase 3 results from SCALP 1 (NCT05910450) and SCALP 2 (NCT05914805) — two identically designed trials in 1,465 men. Both meet their primary endpoint (statistically significant improvement in Target-Area Hair Count vs. vehicle).
The required 12-month safety follow-up completes. This is the longer-duration safety data regulators will actually want to see before reviewing the drug — the topline results alone aren't enough for a filing.
Cosmo has said it plans parallel submissions to the FDA and EMA once the full 12-month dataset is in hand. No submission has been filed yet as of this writing.
The earliest realistic window industry analysts point to for a U.S. pharmacy launch, assuming a clean regulatory review with no delays or requests for additional data — which is common for first-in-class mechanisms.
Other treatments worth watching
Clascoterone isn't the only new mechanism moving through trials right now. VDPHL01, an extended-release oral minoxidil from Veradermics, posted positive Phase 2/3 results in over 500 men with mild-to-moderate pattern hair loss, with a second Phase 3 trial ("Study 304") reading out later in 2026 — if it holds up, it could become the first new pill for baldness approved in roughly 30 years, alongside (not instead of) whatever happens with clascoterone.
Further out and much less proven: stem-cell-derived exosome injections have shown early, promising results in small studies but remain unregulated and not FDA-approved for hair loss anywhere, and genuine hair cloning (lab-grown follicles) is still years from a clinical product despite real 2026 research progress. Neither belongs in the same "nearly here" category as clascoterone or oral minoxidil yet — for a fuller picture of where medication currently stands, see our Minoxidil vs Finasteride vs Dutasteride guide.
Frequently asked questions
What is clascoterone?
Clascoterone is a topical drug that blocks the androgen receptor — the docking site DHT (dihydrotestosterone) uses to trigger the follicle shrinkage behind male pattern baldness. Instead of lowering DHT levels throughout the body, like finasteride or dutasteride do, it works locally at the scalp, blocking DHT from binding there in the first place. It's already FDA-approved at a 1% strength for acne under the brand name Winlevi; the 5% hair-loss version, sometimes called Breezula, is investigational and has completed Phase 3 trials.
Is clascoterone the same as Breezula?
Yes — Breezula is the working brand name Cosmo Pharmaceuticals has used for the 5% clascoterone solution being developed specifically for androgenetic alopecia. The active ingredient in both Breezula (investigational, for hair) and Winlevi (FDA-approved, for acne) is clascoterone; they differ in concentration and intended use.
Is clascoterone available yet?
No. As of this writing it has completed Phase 3 trials but is not FDA- or EMA-approved for hair loss, and there is no legitimate commercial product to buy. Industry timelines point to a 2027 launch at the earliest, after 12-month safety data and regulatory review. Any product sold online today claiming to be "clascoterone for hair loss" is not the approved, trial-tested formulation and should be treated with real skepticism.
Does clascoterone cause the same side effects as finasteride?
The available Phase 3 data says no — reported treatment-emergent adverse events were similar to vehicle (placebo), with no signal of the systemic hormonal side effects (reduced libido, erectile dysfunction) associated with finasteride and dutasteride. That said, the related lower-strength acne formulation (Winlevi 1%) showed reversible hypothalamic-pituitary-adrenal (HPA) axis suppression in about 5% of adults in a pharmacokinetic sub-study, so this is a real class effect worth knowing about, even though the Phase 3 hair-loss trials themselves haven't reported it as an issue so far.
How much will clascoterone cost?
No official price has been announced. Based on the pricing of Winlevi, the already-approved acne version of the same drug, industry observers estimate somewhere around $90–150 per month, and it's very unlikely insurance will cover a hair-loss indication.
Can clascoterone be combined with minoxidil or a hair transplant?
Nothing has been studied yet on combining clascoterone with minoxidil, since it isn't approved or commercially available. Mechanistically there's no obvious conflict — minoxidil and clascoterone work through completely different pathways, similar to how minoxidil is already commonly combined with finasteride. As for transplants, medication (including clascoterone, once available) generally protects existing native hair, while a transplant addresses hair that's already gone — the two are typically complementary, not interchangeable.
What to actually do right now
If you're dealing with hair loss today, clascoterone isn't a reason to wait — it's likely over a year from being available even in a best case. The options that exist right now (minoxidil, finasteride, dutasteride, and transplantation once loss has progressed) are still the ones with real long-term track records. If you want a starting point before talking to a dermatologist or surgeon, our free AI cost calculator estimates your graft count and Norwood stage from a few scalp photos in under a minute, no account needed.
Sources
- SCALP 1 trial registration (NCT05910450), ClinicalTrials.gov
- SCALP 2 trial registration (NCT05914805), ClinicalTrials.gov
- Cosmo Pharmaceuticals — Breezula Phase III topline results
- "Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results", Dermatology Times
- "New hair loss treatment shows significant improvement over placebo", Fox News
- "Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis", Acta Dermato-Venereologica
- WINLEVI (clascoterone) cream 1% — full FDA prescribing label, DailyMed / NIH
- Veradermics — VDPHL01 Phase 2/3 topline results, BusinessWire
A note on this article
This article is for general educational purposes and isn't medical advice. Clascoterone is an investigational drug, not FDA- or EMA-approved for hair loss as of this writing, and is not legitimately available for purchase. Decisions about starting, continuing, or stopping any hair loss treatment should be made with a licensed clinician who knows your medical history.